Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Tepmetko (tepotinib) is a kinase inhibitor approved by the FDA for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Tepmetko selectively inhibits the MET receptor tyrosine kinase, blocking abnormal signaling caused by MET exon 14 skipping alterations that drive tumor growth in this specific subset of lung cancer.
Tepmetko is intended for patients with metastatic NSCLC whose tumors have been confirmed through molecular testing to carry a MET exon 14 skipping alteration.
The recommended dose of Tepmetko is 450 mg taken orally once daily with food.
Tepmetko does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.
Interstitial lung disease or pneumonitis, which can be fatal, has been reported. Tepmetko should be withheld immediately if ILD/pneumonitis is suspected and discontinued if confirmed.
Liver enzyme elevations have been reported. Liver function tests should be monitored before starting treatment and periodically during therapy.
Elevations in pancreatic enzymes have been observed. Patients should be monitored for signs of pancreatic toxicity.
Tepmetko may cause fetal harm. Effective contraception should be used during treatment and for a period after the final dose, as advised by the treating physician.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Tepmetko is manufactured and marketed by EMD Serono, Inc. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating oncologist confirming NSCLC diagnosis and MET exon 14 skipping alteration testing results. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for MET exon 14-altered NSCLC, Tepmetko is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Tepmetko directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Tepmetko should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Tepmetko through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support oncology care coordination and documentation for Tepmetko access.
Delhi's major hospitals assist patients with prescription support and documentation for Tepmetko.
Bangalore's specialist network offers access coordination for eligible lung cancer patients seeking Tepmetko.
Chennai-based oncology specialists coordinate Tepmetko access alongside comprehensive lung cancer care.
Hyderabad's care institutions support patients pursuing Tepmetko therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Tepmetko.
Pune-based specialists assist with prescription support and Tepmetko treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Tepmetko.
Kochi's specialist units assist patients with the documentation needed for Tepmetko access.
Chandigarh's care centers support Tepmetko treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Tepmetko access process.
Lucknow-based centers assist patients pursuing Tepmetko therapy.
Bhubaneswar's institutions support access to Tepmetko for eligible patients.
Guwahati's specialists help coordinate Tepmetko access for patients across the Northeast.
Patients in other cities across India can also access Tepmetko through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: FDA
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
